PRFX

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change +0.14
Percentage change 5.28	%

Peers: PTN TTNP EOLS NBIX PCRX ZTS MRK PFE

Index	-	P/E	-	EPS (ttm)	-8.29	Insider Own	3.27%	Shs Outstand	3.47M	Perf Week	-8.82%
Market Cap	4.76M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.65M	Perf Month	-2.45%
Income	-17.67M	PEG	-	EPS next Q	-	Inst Own	2.55%	Short Float	3.82%	Perf Quarter	-7.00%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	15.17%	Short Ratio	0.02	Perf Half Y	-26.58%
Book/sh	-0.59	P/B	-	EPS next Y	-	ROA	-309.43%	Short Interest	0.06M	Perf Year	-94.19%
Cash/sh	1.64	P/C	1.71	EPS next 5Y	-	ROE	-716.67%	52W Range	1.73 - 61.20	Perf YTD	-16.84%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-28.81%	ROI	-	52W High	-95.44%	Beta	0.63
Dividend TTM	-	Quick Ratio	0.61	Sales past 5Y	0.00%	Gross Margin	-	52W Low	61.53%	ATR (14)	0.33
Dividend Ex-Date	-	Current Ratio	0.61	EPS Y/Y TTM	9.41%	Oper. Margin	-	RSI (14)	43.26	Volatility	7.33% 9.68%
Employees	7	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	48.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-3.64%	Payout	-	Rel Volume	0.03	Prev Close	2.65
Sales Surprise	-	EPS Surprise	-5.77%	Sales Q/Q	-	Earnings	Nov 12	Avg Volume	2.87M	Price	2.79
SMA20	-9.30%	SMA50	-10.57%	SMA200	-51.45%	Trades		Volume	73,260	Change	5.28%

Mar-06-25 11:06AM	PainReform completes acquisition of DeepSolar (TipRanks)
Mar-05-25 11:00AM	PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics (GlobeNewswire)
Feb-18-25 08:30AM	PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity (GlobeNewswire) +31.56%
Dec-28-24 09:17AM	PainReform Faces Setback in Phase 3 Trial for PRF-110 (TipRanks)
Dec-27-24 08:30AM	PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110 (GlobeNewswire) -28.57%
08:30AM	Loading…
Nov-20-24 08:30AM	PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial (GlobeNewswire) -25.71%
Nov-07-24 05:00PM	PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement (GlobeNewswire) +7.16%
Oct-25-24 09:25AM	PainReform cut to Hold at Maxim amid changed market dynamics (TipRanks) -8.87%
Sep-11-24 08:30AM	PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110 (GlobeNewswire) -10.38%
Sep-10-24 09:46AM	PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds (GlobeNewswire) -33.33%
Sep-09-24 12:14PM	Upcoming Stock Splits This Week (September 9 to September 13) Stay Invested (TipRanks)
Aug-21-24 08:30AM	PainReform Bunionectomy Study Observations Confirm Optimal Delivery Method for PRF-110 in Bunionectomy Procedures (GlobeNewswire)
Aug-20-24 08:30AM	PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study (GlobeNewswire) -15.20%
Aug-15-24 08:00AM	PainReform Provides Business Update for the Second Quarter of 2024 (GlobeNewswire)
Aug-12-24 09:00AM	PainReform Announces Development and Successful Manufacturing of New Formulations Providing Anti-Inflammatory and Extended Analgesic Effects (GlobeNewswire)
10:00AM	Loading…
Aug-07-24 10:00AM	PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses (GlobeNewswire)
Aug-05-24 09:00AM	PainReform Ltd. Announces Favorable Wound Healing Data in Human Clinical Trials for PRF-110 (GlobeNewswire) -12.72%
Aug-01-24 08:30AM	PainReform's New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room Temperature (GlobeNewswire)
Jul-24-24 08:30AM	PainReform Files Patent Covering Highly Scalable Manufacturing Process for PRF-110 Following Successful Completion and Testing (GlobeNewswire) -6.36%
Jun-26-24 08:00AM	PainReform Completes Enrollment in the Second Part of its Phase 3 Bunionectomy Trial for PRF-110 (GlobeNewswire)
Jun-14-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) -5.49%
May-31-24 04:15PM	PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification (GlobeNewswire)
May-15-24 10:54PM	PRFX Stock Earnings: PainReform Misses EPS for Q1 2024 (InvestorPlace) -6.31%
04:05PM	PainReform Provides Business Update for the First Quarter of 2024 (GlobeNewswire)
May-08-24 08:30AM	PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com (GlobeNewswire) -6.43%
Apr-18-24 02:19PM	PainReform Announces Closing of $4 Million Public Offering (GlobeNewswire)
Apr-16-24 08:00AM	PainReform Announces Pricing of $4 Million Public Offering (GlobeNewswire) -17.42%
Apr-09-24 10:30AM	EXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing Conditions (Benzinga) -13.21%
09:00AM	PainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions (GlobeNewswire)
Apr-02-24 10:00AM	EXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain Drug (Benzinga)
08:30AM	Loading…
08:30AM	PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy (GlobeNewswire)
Mar-01-24 08:00AM	PainReform Provides Year-End Business Update (GlobeNewswire) +21.42%
Jan-22-24 08:30AM	PainReform to Present at the Microcap Conference in Atlantic City (GlobeNewswire) -7.37%
Jan-03-24 08:30AM	PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief (GlobeNewswire)
Dec-26-23 06:00PM	PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds (GlobeNewswire)
Nov-15-23 04:05PM	PainReform Provides Business Update for the Third Quarter of 2023 (GlobeNewswire) -5.33%
Sep-11-23 08:30AM	PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File (GlobeNewswire)
Sep-07-23 10:00AM	PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary (GlobeNewswire) +6.37%
Sep-05-23 08:30AM	PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City (GlobeNewswire) -7.56%
Aug-10-23 04:05PM	PainReform Provides Business Update for the Second Quarter of 2023 (GlobeNewswire)
06:45AM	7 Stocks Under $10 to Buy for August (InvestorPlace)
Jul-19-23 09:00AM	PainReform Regains Compliance with Nasdaq Continued Listing Requirements (GlobeNewswire) -8.02%
Jul-14-23 02:35PM	PainReform Announces Pricing of $1.5 Million Concurrent Registered Direct Offering and Private Placement (GlobeNewswire) +40.87%
Jul-12-23 09:05AM	PainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private Placement (GlobeNewswire) -51.58%
Jul-03-23 09:01AM	Will PainReform (NASDAQ:PRFX) Spend Its Cash Wisely? (Simply Wall St.) +17.33%
Jun-15-23 08:30AM	PainReform to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21st (GlobeNewswire)
Jun-07-23 04:30PM	PainReform Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery (GlobeNewswire)
May-18-23 09:00AM	PainReform Announces Positive Pharmacokinetic (PK) Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery (GlobeNewswire)
May-15-23 04:45PM	PainReform Provides Business Update for the First Quarter of 2023 (GlobeNewswire)
May-02-23 08:30AM	PainReform CEO to Present at Aegis Virtual Conference on May 4th (GlobeNewswire) -6.26%
May-01-23 08:30AM	PainReform Announces Positive Safety Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery (GlobeNewswire) +17.02%
Apr-17-23 09:00AM	PainReform CEO to Present at the Sequire Investor Summit in Puerto Rico on April 26th (GlobeNewswire)
Mar-28-23 09:10AM	PainReform Completes First Part of Phase 3 Clinical Trial in Patients Undergoing Bunionectomy Surgery (GlobeNewswire) -10.62%
Mar-16-23 08:00AM	PainReform Provides Year-End Business Update; Commences Phase 3 Clinical Trial of PRF-110 in Bunionectomy (GlobeNewswire)
Mar-14-23 08:00AM	PainReform Announces Commencement of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery (GlobeNewswire) +19.86%
Feb-07-23 04:05PM	PainReform Ltd. (NASDAQ: PRFX) Announces Receipt of Extension to Meet the Nasdaqs Minimum Bid Price Requirement (GlobeNewswire) +44.72%
Nov-15-22 08:30AM	PainReform Provides Business Update for the Third Quarter of 2022 (GlobeNewswire)
Nov-08-22 08:30AM	PainReform Provides Further Update on Manufacturing of PRF-110 (GlobeNewswire)
Oct-04-22 09:00AM	PainReform Provides PRF-110 Manufacturing Update (GlobeNewswire)
Sep-01-22 08:00AM	PainReform to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +9.03%
Aug-16-22 08:05AM	PainReform Provides Business Update for the Second Quarter of 2022 (GlobeNewswire)
08:00AM	PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification (GlobeNewswire)
May-17-22 07:00AM	PainReform Provides Business Update for the First Quarter of 2022 (GlobeNewswire) +12.84%
Apr-12-22 09:00AM	PainReform to Present at The Noble Capital Markets' Eighteenth Annual Investor Conference on April 20th (GlobeNewswire)
Mar-21-22 09:25AM	PainReform to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th (GlobeNewswire) +39.64%
Mar-17-22 08:00AM	PainReform Provides Year-End Business Update; on Track to Commence Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief in the Second Half of 2022 (GlobeNewswire) -14.17%
Dec-14-21 08:30AM	PainReform CEO to Participate in the Benzinga All Access Event on December 16th (GlobeNewswire) -5.36%
Nov-22-21 11:58AM	PRFX Stock: 8 Things to Know About PainReform as Shares Trend on Unusually Heavy Volume Today (InvestorPlace)
07:02AM	Will PainReform (NASDAQ:PRFX) Spend Its Cash Wisely? (Simply Wall St.)
Nov-16-21 08:00AM	PainReform Provides Business Update for the Third Quarter of 2021 (GlobeNewswire) -9.45%
Oct-14-21 08:30AM	PainReform to Present at Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021 (GlobeNewswire)
Aug-16-21 08:00AM	PainReform Provides Business Update for the Second Quarter of 2021 (GlobeNewswire) -5.58%
Jun-15-21 12:46PM	Is PainReform Ltd. (PRFX) A Good Stock To Buy Now? (Insider Monkey) -6.95%
May-24-21 06:35AM	We're Not Very Worried About PainReform's (NASDAQ:PRFX) Cash Burn Rate (Simply Wall St.)
May-13-21 08:15AM	PainReform Provides Business Update for the First Quarter of 2021 (GlobeNewswire) +5.58%
Mar-18-21 09:15AM	PainReform Provides Year-End Business Update and Reports Progress Towards Commencing Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief (GlobeNewswire) -11.82%
Mar-11-21 10:43AM	PainReform to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference (GlobeNewswire)
Mar-08-21 09:00AM	PainReform Announces $6.0 Million Private Placement (GlobeNewswire)
Jan-07-21 08:30AM	PainReform to Present at the H.C. Wainwright BioConnect 2021 Conference (GlobeNewswire)
Jan-06-21 08:30AM	PainReform Appoints Rita Keynan as Vice President of Pharmaceutical Operations (GlobeNewswire) -5.17%
Jan-04-21 08:30AM	PainReform Announces Appointment of Lotus Clinical Research as CRO for Phase 3 Clinical Trial of PRF-110 (ACCESSWIRE)
Nov-23-20 08:30AM	PainReform Appoints Senior Pharmaceutical Executive and Finance Veteran Ilan Hadar as Chief Executive Officer (ACCESSWIRE) +10.34%
Nov-12-20 09:00AM	PainReform Welcomes Successful Healthcare and Capital Markets Executive Dr. Ellen Baron to Board of Directors (ACCESSWIRE)
Nov-05-20 08:30AM	PainReform Welcomes Senior Pharmaceutical Executive and Venture Capitalist Augustine Lawlor to Board of Directors (ACCESSWIRE)
Oct-19-20 09:00AM	PainReform Highlights Surgical Advantages of PRF-110 (ACCESSWIRE)
Sep-29-20 07:30AM	PainReform Commences Preparations for Pivotal Phase 3 Clinical Trials (ACCESSWIRE)
Sep-09-20 02:15PM	PainReform Announces Closing of $20.0 Million Initial Public Offering (ACCESSWIRE)

PainReform Ltd. is a pharmaceutical company, which focuses on reformulation of established therapeutics. It offers PRF-110, an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia. The company was founded by Lihu Avitov and Dan Teleman in 2007 and is headquartered in Herzliya, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PainReform Ltd

Upgrade your FINVIZ experience